Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Current and emerging antibody-based immunotherapies in AL amyloidosis

Maximilian Steinhardt • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab Elotuzumab

Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, comments on the efficacy of currently available and emerging antibodies in the treatment of AL amyloidosis, including daratumumab, elotuzumab, and antibodies targeting amyloid deposits. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maximilian Steinhardt

4:18
Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022
2:38
Unmet needs in imaging for the diagnosis of AL amyloidosis
Maximilian Steinhardt • 6 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals